Intra Cellular Therapies reported $88.38M in Selling and Administration Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Acadia Pharmaceuticals ACAD:US USD 78.11M 11.79M
ALKERMES ALKS:US USD 152.78M 2.4M
Aptinyx Inc APTX:US USD 4.65M 547K
Biocryst Pharmaceuticals BCRX:US USD 36.92M 1.1M
Biogen BIIB:US USD 563.3M 9.3M
Bristol Myers Squibb BMY:US USD 1.93B 147M
Cytokinetics CYTK:US USD 48.22M 5.51M
Esperion Therapeutics ESPR:US USD 24.95M 4.65M
Gilead Sciences GILD:US USD 1.21B 144M
Halozyme Therapeutics HALO:US USD 34.07M 23.41M
Intra Cellular Therapies ITCI:US USD 88.38M 11.94M
JAZZ PHA JAZZ:US USD 317.68M 7.99M
Johnson & Johnson JNJ:US USD 6.09B 137M
Marinus Pharmaceuticals MRNS:US USD 13.39M 3.67M
Minerva Neurosciences NERV:US USD 2.84M 6.57K
Nektar Therapeutics NKTR:US USD 22.53M 1.09M
Neurocrine Biosciences NBIX:US USD 186.3M 3.5M
Novartis NVS:US USD 3.4B 185M
Prothena PRTA:US USD 11.99M 963K
Supernus Pharmaceuticals SUPN:US USD 224.63M 124.15M
United Therapeutics UTHR:US USD 98.4M 43.1M
Vanda Pharmaceuticals VNDA:US USD 59.71M 26.71M